

# Topiramate for tobacco dependence

<b>Submission date</b> 30/01/2008	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered
<b>Registration date</b> 27/02/2008	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 31/05/2019	<b>Condition category</b> Mental and Behavioural Disorders	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Marta Alda

**Contact details**  
Avda. Gomez Laguna 52, 4 D  
Zaragoza  
Spain  
50009  
+34 97 651 10 12  
martaalda@hotmail.com

## Additional identifiers

**Clinical Trials Information System (CTIS)**  
Nil known

**ClinicalTrials.gov (NCT)**  
Nil known

**Protocol serial number**  
PI061462

## Study information

**Scientific Title**

Effectiveness of topiramate for tobacco dependence in patients with depression: a randomised, controlled trial

### **Acronym**

N/A

### **Study objectives**

Topiramate is at least as effective like nicotine substitution therapy (NST - the standard treatment) for tobacco dependence.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Ethics approval received from the Ethical Review Board of the Regional Health Authority of Aragon (Spain) in February 2007 (ref: FIS PI06/1462).

### **Study design**

This is a controlled trial with a random allocation of patients into control group (NST) or intervention group (topiramate)

### **Primary study design**

Interventional

### **Study type(s)**

Treatment

### **Health condition(s) or problem(s) studied**

Tobacco dependence, major depressive disorder

### **Interventions**

A multi-component programme for tobacco cessation will be offered to all patients in the study. This is made up of pharmacological therapy and group cognitive-behavioural therapy. The group is made up of 7 - 12 patients with depression and tobacco dependence, and is led by two therapists (a psychologist and a family doctor) trained in group therapy and tobacco cessation. Each session lasts 90 minutes, and the structure of every session and the contents are manualised and based on the standard programmes of this type.

Pharmacological therapy consists of:

1. Control group: Nicotine Substitution Therapy (nicotine patches) at doses of 21 mg/day first and second fortnight, 14 mg/day third fortnight and 7 mg/day fourth and last fortnight
2. Intervention group: Topiramate (oral) 100 - 200 mg/day, during 2 months

The follow-up of the treatments and adverse effects will be made at the appointments described (during the first two months of the intervention).

### **Intervention Type**

Drug

### **Phase**

Not Specified

## **Drug/device/biological/vaccine name(s)**

Topiramate, nicotine

## **Primary outcome(s)**

The major outcome is tobacco cessation in patients with depression. The diagnosis of tobacco dependence will be made with the Spanish version of the Mini-International Neuropsychiatric Interview (MINI), substance dependence module adapted to tobacco (measured at baseline and at the end of study [month 12]). Tobacco abstinence will also be diagnosed by:

1. Self-declared abstinence
2. Self-administered Minnesota tobacco abstinence symptoms, measured at baseline, D (cessation day) -1, weeks 1, 2, 3, 4, 8, 12, and months 4, 5, 6, 8, 10 and 12
3. Expired air carbon monoxide, measured at baseline, D (cessation day) -1, weeks 1, 2, 3, 4, 8, 12, and months 4, 5, 6, 8, 10 and 12
4. Cotinine in saliva, measured at baseline, D (cessation day) -1, weeks 1, 2, 3, 4, 8, 12, and months 4, 5, 6, 8, 10 and 12

## **Key secondary outcome(s)**

The diagnosis of depressive disorder will be made with the Spanish version of the MINI psychiatric interview, depression module, and the severity of the depression with the Spanish version of the Zung Self-Rating Depression Scale (measured at baseline and at the end of study [month 12]). In addition, the following will be also recorded:

1. Tobacco dependence as measured by the Spanish version of the Fagerström test for Nicotine Dependence, measured at baseline, D (cessation day) -1, weeks 1, 2, 3, 4, 8, 12, and months 4, 5, 6, 8, 10 and 12
2. Anxiety trait and state as measured by the Spanish version of the State-Trait Anxiety Inventory (STAI), measured at baseline, D (cessation day) -1, weeks 1, 2, 3, 4, 8, 12, and months 4, 5, 6, 8, 10 and 12
3. Impulsivity as measured by the Spanish version of the Plutchik scale of impulsivity, measured at baseline, D (cessation day) -1, weeks 1, 2, 3, 4, 8, 12, and months 4, 5, 6, 8, 10 and 12
4. Visual analogue scale for efficacy self-perception, measured at baseline, D (cessation day) -1, weeks 1, 2, 3, 4, 8, 12, and months 4, 5, 6, 8, 10 and 12
5. Pharmacological side-effects

## **Completion date**

31/12/2009

## **Eligibility**

### **Key inclusion criteria**

1. Patients aged 18 - 65 years, either sex
2. Able to understand and read Spanish
3. Fulfill criteria for major depression (Diagnostic and Statistical Manual of Mental Disorders, 4th edition [DSM-IV] criteria)
4. Scores on the Zung Self-Rating Depression Scale less than 60 (implying minimal to mild depression)
5. Smoke more than 20 cigarettes/day
6. Fulfil preparation state of change according to Prochaska and DiClemente classification
7. Voluntarily ask for a tobacco cessation therapy
8. Sign informed consent

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

**Total final enrolment**

180

**Key exclusion criteria**

1. Active psychosis and/or treatment with antipsychotic drugs
2. Alcohol or drug abuse
3. Pregnancy or lactation

**Date of first enrolment**

01/04/2008

**Date of final enrolment**

31/12/2009

**Locations****Countries of recruitment**

Spain

**Study participating centre**

Avda. Gomez Laguna 52, 4 D

Zaragoza

Spain

50009

**Sponsor information****Organisation**

The Carlos III Health Institute (Instituto de Salud Carlos III) (Spain)

ROR

<https://ror.org/00ca2c886>

## Funder(s)

### Funder type

Government

### Funder Name

Carlos III Health Institute of the Spanish Ministry of Health and Consumption (Fondo de Investigaciones Sanitarias - Instituto de Salud Carlos III-Ministerio de Sanidad y Consumo) (Spain) (ref: PI06/1462)

## Results and Publications

### Individual participant data (IPD) sharing plan

#### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	07/05/2008	31/05/2019	Yes	No
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes